Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apex BiotechnologyTPE:1733 -1.42%80 5-Year Yield-on-Cost % is 4.38 as of Aug. 02, 2026, which is 3% below its 10-year median of 4.51. GuruFocus rates TPE:1733 with a GF Score™ of 80/100 and a GF Value™ of NT$29.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 150 Biotechnology companies, Apex Biotechnology ranks better than 74% on this metric.
Apex Biotechnology's yield on cost for the quarter that ended in Mar. 2026 was 4.38.
The historical rank and industry rank for Apex Biotechnology's 5-Year Yield-on-Cost % or its related term are showing as below:
TPE:1733'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.96 Med: 4.51 Max: 11.71
Current: 4.38
During the past 13 years, Apex Biotechnology's highest Yield on Cost was 11.71. The lowest was 0.96. And the median was 4.51.
TPE:1733's 5-Year Yield-on-Cost % is ranked better than 74% of 150
companies
in the Biotechnology industry
Industry Median: 1.715
vs TPE:1733: 4.38
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Apex Biotechnology 5-Year Yield-on-Cost % Related Terms
TPE:1733 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Apex Biotechnology's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Apex Biotechnology (TPE:1733) has a 5-Year Yield-on-Cost % of 4.38 as of Aug. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Apex Biotechnology and its competitors. This is near median its historical median of 4.51. Over the past decade, Apex Biotechnology's 5-Year Yield-on-Cost % has ranged from 0.96 to 11.71. According to the industry distribution chart, Apex Biotechnology ranks #39 out of 150 companies in the Biotechnology industry, placing it in the top 26%.
Is Apex Biotechnology's 5-Year Yield-on-Cost % too high?
Apex Biotechnology's current 5-Year Yield-on-Cost % of 4.38 is near median its 10-year median of 4.51. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 11.71. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.72. Apex Biotechnology's value of 4.38 is 155.4% above this industry median. Based on the distribution chart, Apex Biotechnology ranks #39 out of 150 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #39 out of 150 companies for 5-Year Yield-on-Cost %. This puts Apex Biotechnology in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 1.72. Apex Biotechnology's value of 4.38 is 155.4% above this benchmark. Historically, Apex Biotechnology's own 5-Year Yield-on-Cost % has ranged from 0.96 to 11.71 over the past decade. While the company's 10-year median is 4.51 vs. the industry median of 1.72, Apex Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.72, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current 5-Year Yield-on-Cost % of 4.38 is 155.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current 5-Year Yield-on-Cost % is 4.38, which is near median its own 10-year median of 4.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.80, compared to a current price of NT$31.30 — trading 5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 4.38, which is near median its 10-year median of 4.51 and 155.4% above the Biotechnology industry median of 1.72. Apex Biotechnology's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current 5-Year Yield-on-Cost % is 4.38 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued.
The current stock price of NT$31.30 is trading 5% above its estimated GF Value™ of NT$29.80.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
5-Year Yield-on-Cost %: 4.38 (near median its 10-year median of 4.51)
GF Value™: NT$29.80 vs. price of NT$31.30 (5% above fair value)
Industry Position: 155.4% above the Biotechnology median (#39 of 150)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
80GF Score
Get the complete analysis for TPE:1733
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
